Global Trials -Innovation or Exploitation

I have always admired the optimism of Indian CEOs when they talk about welcoming global companies for partnerships in Research & Development. It sounds glamorous—India as the next big hub for innovation, collaborating with giants to create life‑saving molecules.

But let’s pause for a reality check.

What these leaders often fail to recognize—or perhaps conveniently ignore—is how Indian laws can be misinterpreted, bent, and squeezed to accommodate such partnerships. And when it comes to bending rules, Indians are masters of jugaad. The global players know this all too well.

India: A Heaven for Global Giants

In developed countries, five phases of clinical trials are a regulatory mountain. Strict ethical standards, strong patient rights, and government oversight make it nearly impossible to push a drug through without immense scrutiny.

India, on the other hand, has long been a paradise for them. Easy recruitment, weaker regulatory checks, and a healthcare system desperate for access make us the perfect playground. And yes, often, we end up as the guinea pigs.

The Power Equation Has Shifted

Here’s the irony: Indian pharma companies once demanded a bigger slice of the pie in these partnerships. But today, the multinational corporations (MNCs) have become smarter. They don’t bother with trust, compliance, or value creation beyond what suits their goals.

Instead, they dictate terms. Co‑promotion is allowed, sure—but always at the price they fix. The balance of power is crystal clear.

The Scientific Flaw Nobody Talks About

Now let’s get into the science. Can a clinical trial conducted in India—or Africa, for that matter—be a true reflection of efficacy and safety in the West?

The answer is a loud No.

Physiological differences matter. Body structure, genetic makeup, metabolism, diet, and environmental exposures—all these factors shape how a drug works in one population versus another. That’s precisely why China flatly refuses to allow MNCs to run trials on its citizens.

Yet India opens its doors, under the illusion of “global research collaboration.”

The Bitter Truth

At the end of the day, it’s not about science, or ethics, or even patient welfare. It’s about one thing: money.

Global giants need a testing ground, and India—with its patchy laws and willingness to compromise—offers just that. Our leaders cheer these partnerships, but the truth is far less flattering. We are not at the negotiation table; we are on the examination table.

And until we strengthen our regulatory backbone, the story of Indian participation in global drug trials will remain less about innovation—and more about exploitation.

---